Search Results - "Ludovini, V"

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients by D'Incecco, A, Andreozzi, M, Ludovini, V, Rossi, E, Capodanno, A, Landi, L, Tibaldi, C, Minuti, G, Salvini, J, Coppi, E, Chella, A, Fontanini, G, Filice, M E, Tornillo, L, Incensati, R M, Sani, S, Crinò, L, Terracciano, L, Cappuzzo, F

“…Background: Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It…”
Get full text

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial by Lorusso, D., Scambia, G., Pignata, S., Sorio, R., Amadio, G., Lepori, S., Mosconi, A., Pisano, C., Mangili, G., Maltese, G., Sabbatini, R., Artioli, G., Gamucci, T., Di Napoli, M., Capoluongo, E., Ludovini, V., Raspagliesi, F., Ferrandina, G.

“…Current evidence suggest that trabectedin is particularly effective in cells lacking functional homologous recombination repair mechanisms. A prospective phase…”
Get full text

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients by Ludovini, V., Bellezza, G., Pistola, L., Bianconi, F., Di Carlo, L., Sidoni, A., Semeraro, A., Del Sordo, R., Tofanetti, F.R., Mameli, M.G., Daddi, G., Cavaliere, A., Tonato, M., Crinò, L.

“…Insulin-like growth factor receptor-1 (IGFR-1) represents a novel molecular target in non-small-cell lung cancer (NSCLC). IGFR-1 and epidermal growth factor…”
Get full text

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival by Ludovini, V., Gori, S., Colozza, M., Pistola, L., Rulli, E., Floriani, I., Pacifico, E., Tofanetti, F. R., Sidoni, A., Basurto, C., Rulli, A., Crinò, L.

“…Background: We explored the correlation between serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) and tissue HER2 status, their…”
Get full text

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations by Ludovini, V., Bianconi, F., Pistola, L., Minotti, V., Chiari, R., Colella, R., Bellezza, G., Tofanetti, F. R., Siggillino, A., Baldelli, E., Flacco, A., Giuffrida, D., Sidoni, A., Crinò, L.

“…Background We present a comprehensive analysis of KRAS , PIK3CA , MET, and non-sensitizing EGFR mutations in advanced non-small cell lung cancer (NSCLC)…”
Get full text

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer by Ricciuti, B., Brambilla, M., Cortellini, A., De Giglio, A., Ficorella, C., Sidoni, A., Bellezza, G., Crinò, L., Ludovini, V., Baglivo, S., Metro, G., Chiari, R.

“…Purpose KRAS mutation has been associated with enhanced dependency on the folate metabolism in preclinical studies. However, whether KRAS mutation correlates…”
Get full text

Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren’s syndrome by Bartoloni, E, Ludovini, V, Alunno, A, Pistola, L, Bistoni, O, Crinò, L, Gerli, R

“…High levels of serum and/or plasma circulating DNA (cDNA) have been described in patients with systemic autoimmune diseases (SADs). However, the role of this…”
Get full text

Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels by Ricciuti, B., Chiari, R., Tofanetti, F.R., De Giglio, A., Porreca, R., Brambilla, M., Sperduti, I., Bellezza, G., Mencaroni, C., Siggillino, A., Zicari, D., Baldi, A., Ludovini, V., Metro, G.

Get full text

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab by Gori, S., Sidoni, A., Colozza, M., Ferri, I., Mameli, M. G., Fenocchio, D., Stocchi, L., Foglietta, J., Ludovini, V., Minenza, E., De Angelis, V., Crinò, L.

“…Background: In an attempt to identify markers of resistance to trastuzumab, we evaluated both the profiling of human epidermal growth factor receptor 2…”
Get full text

Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target by Pilotto, S., Simbolo, M., Gkountakos, A., Mafficini, A., Vicentini, C., Sperduti, I., Ludovini, V., Chiari, R., Novello, S., Milella, M., Carbognin, L., Caregnato, E., Santo, A., Infante, M., Brunelli, M., Corbo, V., Scarpa, A., Tortora, G., Bria, E.

Get full text

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients by CAPPUZZO, F, TOSCHI, L, FRANKLIN, W. A, CRINO, L, BUNN, P. A, HIRSCH, F. R, VARELLA-GARCIA, M, DOMENICHINI, I, BARTOLINI, S, CERESOLI, G. L, ROSSI, E, LUDOVINI, V, CANCELLIERI, A, MAGRINI, E, BEMIS, L

“…In non-small-cell lung cancer (NSCLC), sensitivity to tyrosine kinase inhibitors (TKIs) is associated with activating mutations and genomic gain of the…”
Get full text

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients by Ludovini, V., Flacco, A., Bianconi, F., Ragusa, M., Vannucci, J., Bellezza, G., Chiari, R., Minotti, V., Pistola, L., Tofanetti, F. R., Siggillino, A., Baldelli, E., Sidoni, A., Daddi, N., Puma, F., Varella-Garcia, M., Crinò, L.

“…Background Insulin-like growth factor 1 receptor (IGF1R) represents a novel molecular target in non-small-cell-lung cancer (NSCLC). IGF1R and epidermal growth…”
Get full text

Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib by Gregorc, V, Hidalgo, M, Spreafico, A, Cusatis, G, Ludovini, V, Ingersoll, RG, Marsh, S, Steinberg, SM, Viganò, MG, Ghio, D, Villa, E, Sparreboom, A, Baker, SD

“…The purpose of this study was to evaluate associations between germline epidermal growth factor receptor (EGFR) variants involved in transcriptional regulation…”
Get full text

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation by Metro, Giulio, Chiari, R., Mare, M., Giannarelli, D., Tofanetti, F. R., Minotti, V., Ferraldeschi, M., Giuffrida, D., Marcomigni, L., Bennati, C., Fischer, M. J., Meacci, M., Bellavita, R., Pistola, L., Ludovini, V., Crinò, L.

“…Purpose In the present study, the combination of carboplatin (CBDCA) plus pemetrexed (PMX) for the treatment of patients with platinum-pretreated,…”
Get full text

Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients by LUDOVINI, V, SIDONI, A, RODINO, C, SABBATINI, R, MAZZOCCHI, B, BUCCIARELLI, E, TONATO, M, COLOZZA, M, PISTOLA, L, BELLEZZA, G, DE ANGELIS, V, GORI, S, MOSCONI, A. M, BISAGNI, G, CHERUBINI, R, BIAN, A. Rosa

“…In this study, we retrospectively evaluated the expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in 228 and 213 specimens,…”
Get full text

6088 POSTER KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients by Landi, L, Biagioni, F, Ludovini, V, Sacconi, A, D'Arcangelo, M, Destro, A, Blandino, G, Roncalli, M, Crinö, L, Cappuzzo, F

Get full text

1098 POSTER Gene Expression Profiling of Lung Adenocarcinoma Stage I Patients: Risk for Relapse Disease by Siggillino, A, Ludovini, V, Bianconi, E, Piobbico, D, Fazia, M.A. Delia, Tofanetti, F.R, Ragusa, M, Bellezza, G, Servillo, G, Crinö, L

Get full text

128PD EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS by Crinò, L, Pistola, L, Bianconi, F, Chiari, R, Meacci, M, Colella, R, Giuffrida, D, Tofanetti, F.R, Flacco, A, Ludovini, V

Get full text

Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients by Mihaylova, Zh, Ludovini, V, Gregorg, V, Floriani, I, Pistola, L, Toffaneti, Fr, Ferraldeschi, M, Spreafico, A, Ceresoli, G L, Bellet, M, Darwish, S, Tonato, M, Raynov, J

“…To evaluate serum changes of matrix metalloproteinases (MMPs) 2 and 9, vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)…”
Get more information

9081 A phase II retrospective trial of Carboplatin (CBDCA) and Alimta in refractory non-small cell lung cancer (NSCLC) with genetic polymorphisms analysis by Ludovini, V, Pistola, L, Floriani, I, Meacci, M, Chiari, R, Stocchi, L, Tofanetti, F.R, Mare, M, Giuffrida, D, Crinò, L

Get full text